NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Zosano Pharma Corporation (NASDAQCM:ZSAN) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
The investigation concerns whether the Company’s filings with the SEC in connection with its January 2015 Initial Public Offering contained untrue statements or omitted material information, and whether the Company adequately disclosed the risks and viability of its lead osteoporosis drug program, ZP-PTH. Zosano sold 6.5 million shares of stock in its initial public offering on January 27, 2015 at $11.00 per share. Zosano stock has plummeted, however, to a recent close of just $1.96 per share. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510